About Aveo Oncology
Aveo Oncology is a company based in Cambridge (United States) founded in 2001 was acquired by LG Chem in October 2022. It operates as a HealthTech. Aveo Oncology has raised $266.4 million across 11 funding rounds from investors including Bessemer Venture Partners, LG Chem and Biogen. The company has 114 employees as of December 31, 2022. Aveo Oncology offers products and services including FOTIVDA, Ficlatuzumab, and AV-380. Aveo Oncology operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Cambridge, United States
- Employees 114 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Aveo Pharmaceuticals, Inc.
-
Annual Revenue
$42.3 M603as on Dec 31, 2021
-
Net Profit
-
EBITDA
-
Total Equity Funding
$266.4 M (USD)
in 11 rounds
-
Latest Funding Round
-
Investors
Bessemer Venture Partners
& 16 more
-
Employee Count
114
as on Dec 31, 2022
-
Acquired by
LG Chem
(Oct 18, 2022)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Aveo Oncology
Aveo Oncology offers a comprehensive portfolio of products and services, including FOTIVDA, Ficlatuzumab, and AV-380. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
FOTIVDA is developed for treating cancer patients effectively.
Ficlatuzumab is researched for potential cancer treatment solutions.
AV-380 is explored for innovative cancer therapy options.
Unlock access to complete
Funding Insights of Aveo Oncology
Aveo Oncology has successfully raised a total of $266.4M across 11 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 11
- Last Round Last Round
-
First Round
First Round
(01 Oct 2003)
- Investors Count 16
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2016 | Amount | Post-IPO - Aveo Oncology | Valuation |
investors |
|
| May, 2011 | Amount | Post-IPO - Aveo Oncology | Valuation |
investors |
|
| Nov, 2010 | Amount | Post-IPO - Aveo Oncology | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Aveo Oncology
Aveo Oncology has secured backing from 17 investors, including venture fund and institutional investors. Prominent investors backing the company include Bessemer Venture Partners, LG Chem and Biogen. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are offered to startups by NEA.
|
Founded Year | Domain | Location | |
|
Venture debt financing is provided to companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital investments and support for entrepreneurs in technology and innovation sectors.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Aveo Oncology
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Aveo Oncology
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Aveo Oncology Comparisons
Competitors of Aveo Oncology
Aveo Oncology operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Aveo Oncology
Frequently Asked Questions about Aveo Oncology
When was Aveo Oncology founded?
Aveo Oncology was founded in 2001 and raised its 1st funding round 2 years after it was founded.
Where is Aveo Oncology located?
Aveo Oncology is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Is Aveo Oncology a funded company?
Aveo Oncology is a funded company, having raised a total of $266.4M across 11 funding rounds to date. The company's 1st funding round was a Post-IPO of $60.8M, raised on Oct 01, 2003.
How many employees does Aveo Oncology have?
As of Dec 31, 2022, the latest employee count at Aveo Oncology is 114.
What is the annual revenue of Aveo Oncology?
Annual revenue of Aveo Oncology is $42.3M as on Dec 31, 2021.
What does Aveo Oncology do?
Aveo Oncology, a subsidiary of LG Chem, is dedicated to the development of innovative medicines for cancer patients. The company is engaged in the biotechnology sector with a primary focus on oncology. Solutions such as FOTIVDA, Ficlatuzumab, and AV-380 are being researched and developed to improve patient outcomes. The organization is headquartered in Boston, Massachusetts, and is committed to advancing scientific research and partnerships in the field of cancer treatment.
Who are the top competitors of Aveo Oncology?
Aveo Oncology's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
What products or services does Aveo Oncology offer?
Aveo Oncology offers FOTIVDA, Ficlatuzumab, and AV-380.
Who are Aveo Oncology's investors?
Aveo Oncology has 17 investors. Key investors include Bessemer Venture Partners, LG Chem, Biogen, Hercules Capital, and Flagship Pioneering.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.